arrow
D

Davey M. Smith

Harvard University
H指数:82
被引数:4.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolution

吸入型干扰素-β1a对SARS-CoV-2多样性和进化的影响

2026-07-070
PRE
Histone decrotonylation plays a distinct role in HIV latency

组蛋白脱巴豆酰化在HIV潜伏期中发挥独特作用

2026-04-100
OA
Relationship Between Opioid Use, Depression, and Quality of Life Among Persons With HIV at End of Life

艾滋病终末期患者中阿片类药物使用、抑郁症与生活质量之间的关系

2025-10-190
PRE
Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy

肌肉内或静脉内给予抗病毒单克隆抗体疗法快速清除可培养的SARS-CoV-2

2025-09-010
OAAI
Evaluating Viral Load Sampling Schemes and Swabbing Methods for Optimal Surrogacy

评估病毒载量采样方案和拭子采样方法以实现最佳替代指标

2025-09-010
OA
Motivations, acceptability and ethical considerations for interventional HIV cure research at the end of life: perspectives from long-term survivors of HIV in the United States

干预性HIV治愈研究在生命终末期的动机、可接受性及伦理考量:来自美国HIV长期生存者的视角

2025-08-240
PRE
Vaccine hesitancy and economic hardship: A latent class analysis of racial and ethnic minority communities at high risk of COVID-19 infection in Southern California

疫苗接种犹豫与经济困难:对南加州高风险COVID-19感染种族和族裔少数群体的潜类分析

2025-07-100
OAAI
Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel
2025-02-181
PRE
Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial
2025-02-171
OAAI
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies

Tixagevimab/cilgavimab 或安慰剂用于 ACTIV-2 研究:安全性、药代动力学及中和抗体和抗药抗体

2025-02-010
OAAI